Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey

BackgroundThe Oncotype Dx recurrence score (ODx-RS) guides the adjuvant chemotherapy decision-making process for patients with early-stage hormone receptor-positive, HER-2 receptor-negative breast cancer. This study aimed to evaluate survival and its correlation with ODx-RS in pT1-2, N0-N1mic patien...

Full description

Bibliographic Details
Main Authors:	Çağlar Ünal, Tolga Özmen, Çetin Ordu, Kezban Nur Pilanci, Ahmet Serkan İlgün, Erhan Gökmen, Elvina Almuradova, Mustafa Özdoğan, Nilüfer Güler, Cihan Uras, Halil Kara, Orhan Demircan, Selver Işık, Gül Alço, Pınar Saip, Esra Aydın, Tomris Duymaz, Filiz Çelebi, Kanay Yararbaş, Gursel Soybir, Vahit Ozmen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Oncology
Subjects:	clinicopathologic characteristics early-stage breast cancer lymph node-negative Oncotype DX® recurrence score 21 genes
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1151733/full

Similar Items

Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey
by: Vahit Özmen, et al.
Published: (2016-07-01)

MRI Radiomics and Machine Learning for the Prediction of Oncotype Dx Recurrence Score in Invasive Breast Cancer
by: Valeria Romeo, et al.
Published: (2023-03-01)

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
by: Xiaofu Zhu, et al.
Published: (2021-02-01)

Predicting Chemotherapy Benefit across Different Races in Early-Stage Breast Cancer Patients Using the Oncotype DX Score
by: Vikram R. Shaw, et al.
Published: (2023-06-01)

Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer
by: Ran Song, et al.
Published: (2023-09-01)

A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©
by: Matthew G. Davey, et al.
Published: (2022-07-01)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
by: Didi Feldman, et al.
Published: (2023-10-01)

Precision Medicine in Breast Cancer: Do MRI Biomarkers Identify Patients Who Truly Benefit from the Oncotype DX Recurrence Score<sup>®</sup> Test?
by: Francesca Galati, et al.
Published: (2022-11-01)

The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer
by: Atilla Soran, et al.
Published: (2020-04-01)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
by: Richard Buus, et al.
Published: (2021-02-01)

Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center
by: Dániel Deme, et al.
Published: (2024-04-01)

Lymphovascular invasion in hormone-positive, human epidermal growth factor-negative, low-burden axillary disease in early breast cancer patients tested for oncotype DX recurrence score
by: Abdalla Saad Abdalla Al-Zawi, et al.
Published: (2022-07-01)

The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center
by: Stephane Thibodeau, et al.
Published: (2019-07-01)

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center
by: John Loggie, et al.
Published: (2024-06-01)

Assessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorization
by: Çağlar Ünal, et al.
Published: (2023-10-01)

Oncotype Dx Score, HER2 Low Expression, and Clinical Outcomes in Early-Stage Breast Cancer: A National Cancer Database Analysis
by: Arya Mariam Roy, et al.
Published: (2023-08-01)

Benefits and Applications of Oncotype DX Breast Recurrence Score Testing among Breast Cancer Patients: Current Recommendations and Controversies.
by: Elena-Diana Chiru, et al.
Published: (2023-06-01)

Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancer
by: Eoin P. Kerin, et al.
Published: (2022-12-01)

Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study
by: Arif Ali Awan, et al.
Published: (2024-02-01)

The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment
by: Kathleen Iles, et al.
Published: (2022-03-01)

MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification
by: Ünal Ç, et al.
Published: (2023-09-01)

Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
by: Luca Licata, et al.
Published: (2023-06-01)

Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis
by: Nickolas Stabellini, et al.
Published: (2023-04-01)

A randomised controlled trial of Pre-Operative Oncotype DX testing in early-stage breast cancer (PRE-DX study) - Study protocol.
by: Matthew Northgraves, et al.
Published: (2024-01-01)

Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer
by: Sung Jun Ma, et al.
Published: (2023-04-01)

Integrated Multiparametric Radiomics and Informatics System for Characterizing Breast Tumor Characteristics with the OncotypeDX Gene Assay
by: Michael A. Jacobs, et al.
Published: (2020-09-01)

The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX<sup>®</sup> Testing
by: Bradley M. Turner, et al.
Published: (2023-01-01)

Identifying Clinicopathological Factors Associated with Oncotype DX<sup>®</sup> 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada
by: Simon Gagnet, et al.
Published: (2021-08-01)

Racial/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer
by: Jasmin Gill, et al.
Published: (2024-04-01)

Comparison between Oncotype DX test and standard prognostic criteria in estrogen receptor positive early-stage breast cancer
by: Marcelo Roberto Pereira Freitas, et al.
Published: (2011-09-01)

Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study
by: Leandro Jonata Carvalho Oliveira, et al.
Published: (2022-12-01)

Clinical application of the 21-gene oncotype recurrence score in an older cohort: A single center experience
by: E.D. Chiru, et al.
Published: (2023-10-01)

P151 The prediction of Oncotype DX risk group using clinicopathologic factors in patients with HR+/HER2- early breast cancer
by: R. Song, et al.
Published: (2023-03-01)

Potential Refinement of Recurrence Score by pSTAT3 Status
by: Albert Grinshpun, et al.
Published: (2022-02-01)

Prediction of a Multi-Gene Assay (Oncotype DX and Mammaprint) Recurrence Risk Group Using Machine Learning in Estrogen Receptor-Positive, HER2-Negative Breast Cancer—The BRAIN Study
by: Jung-Hwan Ji, et al.
Published: (2024-02-01)

Prognostic Comparison between Oncotype DX<sup>®</sup> and a 23-Gene Classifier, RecurIndex<sup>®</sup>, on the Taiwan Breast Cancer Population
by: Chuan-Hsun Chang, et al.
Published: (2022-11-01)

P168 OncotypeDX RS new TAILORx cut-offs: omitting Chemotherapy in more patients aged >50 years with Early Breast Cancer
by: C. MarKopoulos, et al.
Published: (2023-03-01)

P152 The impact of the TailorX and RxPonder studies and the use of Oncotype Dx in clinical practice: A single Breast Cancer Center experience
by: D. Nasikas, et al.
Published: (2023-03-01)

Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study
by: Çağlar Ünal, et al.
Published: (2023-10-01)

Recurrence Score<sup>®</sup> Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial
by: Dominik Dannehl, et al.
Published: (2022-10-01)